azd9496
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 22, 2014 (NCT02248090)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Estrogen receptorINHIBITOR
Estrogen receptor inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- azd9496
- azd9496
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03236974 | Phase 1 | Oct 5, 2017 | AstraZeneca |
| NCT02780713 | Phase 1 | Jun 1, 2016 | AstraZeneca, Parexel |
| NCT02248090 | Phase 1 | Oct 22, 2014 | AstraZeneca, Nashville Hospital, United States |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 3 | 3 | 1 | 2014 |
| Nashville Hospital, United States | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Parexel | For profit | 1 | 0 | 1 | 2016 |
3 organizations
Page 1 / 1